Pharsight

1. List of Kisqali Femara Co-pack (copackaged) drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8324225	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Jun, 2028 (5 years from now)
US8685980	NOVARTIS	Pyrrolopyrimidine compounds and their uses	May, 2030 (7 years from now)
US8415355	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Mar, 2031 (8 years from now)
US9193732	NOVARTIS	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof	Nov, 2031 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9416136	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Aug, 2029 (6 years from now)
US8962630	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Dec, 2029 (6 years from now)
US9868739	NOVARTIS	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof	Nov, 2031 (8 years from now)
US10799506	NOVARTIS	Ribociclib tablet	Apr, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Mar 13, 2022
New Patient Population (NPP)	Dec 10, 2024

NCE-1 date: March, 2021

Market Authorisation Date: 04 May, 2017

Treatment: Treatment of pre/perimenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; As initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL